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Abstract
Bacterial vaginosis is a polymicrobial syndrome. The most impor-
tant marker for bacterial vaginosis is the presence of Gardnerella vag-
inalis and Atopobium vaginae. In this study, the in vitro susceptibilities
to metronidazole and secnidazole of 16 strains of A. vaginae were
tested with the agar dilution method. We observed an MIC range
for metronidazole of 4–64 mg/L (MIC50, 8 mg/L; MIC90, 32 mg/L)
and an MIC range for secnidazole of 4–128 mg/L (MIC50, 16 mg/L;
MIC90, 64 mg/L). According to these findings, we can conclude that
the activity of secnidazole is similar to that of metronidazole.
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Bacterial vaginosis (BV) is a polymicrobial syndrome in which
the lactobacilli of the normal microflora are overgrown by
Gram-positive and Gram-negative bacteria and for which
high concentrations of Gardnerella vaginalis and, recently,
Atopobium vaginae have been recognized as important micro-
biological markers [1,2], whereby a high concentration of
A. vaginae is a better marker than a high concentration of
G. vaginalis [2,3]. Both species are frequently found together
in the biofilm formed in BV [4]. Metronidazole and clindamy-
cin are the preferred treatment regimens. In this study, the
in vitro activities of secnidazole against members of the Atopo-
bium group were tested.
Secnidazole is a member of the family of 5-nitro-imidaz-
oles, as is metronidazole. Secnidazole could be a valuable
alternative for metronidazole, owing to a longer half-life and
fewer side effects [5]. The longer half-life makes single-dose
applications possible, which could avoid treatment failures
caused by patient compliance. Previously, the susceptibility
to secnidazole was determined by Dubreuil et al. [6] for
several strictly anaerobic bacteria, including bacteria involved
in BV, although A. vaginae was not included. High MIC
values of A. vaginae for metronidazole have been reported
[7,8].
For this study, 16 strains of A. vaginae, two strains of Atop-
obium parvulum and one strain each of Atopobium rimae and
Atopobium minutum were tested. Six strains of A. vaginae
(CCUG 44258, CCUG 42099, CCUG 44125, CCUG
44061 and CCUG 38953T) and one strain each of A. minutum
(CCUG 31167), A. rimae (CCUG 31168) and A. parvulum
(CCUG 32760) were obtained from the Culture Collection
of the University of Go¨teborg. All other strains were clinical
vaginal isolates obtained during studies at the Laboratory
Bacteriology Research from 2003 until 2006. In addition, two
quality control strains were included, i.e. Bacteriodes thetaiota-
omicron CCUG 34778 and Bacteriodes fragilis CCUG 4856.
For both metronidazole (Dr Ehrenstorfer, Augsburg, Ger-
many) and secnidazole (Ethypharm, Houdan, France), a stock
solution of 5120 mg/L was prepared. Secnidazole was dis-
solved in dimethylsulphoxide (DMSO), and the DMSO con-
centration was afterwards adjusted to 10% with sterile
distilled water. Two-fold dilution series in distilled water
were made for both antibiotics, as previously described [9].
One millilitre of each dilution was incorporated in 19 mL
of Mueller–Hinton agar, supplemented with 5% sterile defi-
brinated sheep blood (E&O Laboratories, Bonnybridge, UK)
at 50C. Plates contained Mueller–Hinton agar with serial
two-fold dilutions of antimicrobial agents between 256 and
0.5 mg/L, and two negative control plates to which 1 mL of
distilled water or 1 mL of a 10% DMSO solution was added.
The plates were dried with open lids for 1 h and stored at
4C. Plates were pre-incubated for 5 h in an anaerobic
workstation (BugBoxPlus; LED techno, Heusden-Zolder,
Belgium).
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Strains were cultured on Mueller–Hinton agar + 5% sheep
blood (Becton Dickinson, Erembodegem, Belgium) for 72 h
in an anaerobic workstation (BugBoxPlus; LED techno) at
37C. Strains were harvested and suspended in sterile saline
(0.9% NaCl) at a density equal to a McFarland standard (Bio-
me´rieux, Boxtel, The Netherlands) of 0.5. Immediately after
inoculation of the strains with a Steers replicator (Mast Sys-
tems, London, UK), plates were incubated in the anaerobic
workstation for 72 h at 37C.
The MIC values for metronidazole and secnidazole were,
respectively, 1 and 2 mg/L for both control strains, B. fragilis
CCUG 4856 and B. thetaiotaomicron CCUG 34778; these
values are within the expected range. Both negative control
plates showed dense growth for all strains, and no differ-
ence was seen between the negative control plates contain-
ing 0.5% DMSO and distilled water. For the 16 strains of
A. vaginae, we observed an MIC range for metronidazole of
4–64 mg/L (MIC50, 8 mg/L; MIC90, 32 mg/L) and an MIC
range for secnidazole of 4–128 mg/L (MIC50, 16 mg/L;
MIC90, 64 mg/L). The results for all the strains are listed in
Table 1.
This study was carried out to compare the in vitro MIC
values of Atopobium strains for secnidazole in comparison
with metronidazole. It is difficult to link these values to sus-
ceptibility breakpoints, for several reasons. Different authori-
ties (CLSI, EUCAST) have determined breakpoints for
resistance for metronidazole, but not yet for secnidazole.
CLSI breakpoints are general for all nitro-imidazole mole-
cules, but EUCAST criteria are only specified for metronida-
zole. In addition, not much is known about the
pharmacokinetics of these compounds in the vagina.
With use of a topical treatment, high concentrations of
metronidazole can be achieved, although the most common
administration route is the oral one. Davis et al. [10]
reported that a maximum concentration of 26 mg/L could be
reached in the vaginal fluid 6 h after oral administration of
2 g of metronidazole, at which time it equals the serum con-
centration. These data correspond to those of Matilla et al.
[11], showing that the maximal serum concentration of
9.4 mg/L is reached 1.9 h after oral administration of 500 mg
of metronidazole. The half-life of metronidazole ranges from
7 to 9.7 h, in contrast to the half-life of secnidazole, which
ranges from 17 to 28.8 h with a Cmax of 35.7–46.3 mg/L for
a 2-g dose [12]. Recent studies confirm these previous
results (B. Dickey, 2009, to be published). Therefore, it
seems appropriate that EUCAST and CLSI should propose
new criteria for secnidazole in accordance with these
findings.
Bradshaw et al. [2] reported that, despite a significant
reduction of A. vaginae numbers after treatment with oral
metronidazole (400 mg twice daily for 7 days), BV cases with
both A. vaginae and G. vaginalis had much higher rates of
recurrent BV (83%) than those with G. vaginalis only (38%).
This could possibly be explained by acquired resistance, e.g.
through the presence and activation of nim genes [13] or by
the biofilm that is present in BV [4]. According to a recent
meta-analysis of published results [14], treatment of both
partners may be important for the eradication of BV.
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Abstract
In 2007, a significant increase in acquired ampC genes in Entero-
bacteriaceae from 0.06% in 1999 to 1.3% was observed. Proteus
mirabilis showed the highest prevalence (0.95%) and CMY-2 was
the most prevalent AmpC enzyme (66.7%). Other enzymes such
as CMY-4, DHA-1, ACC-1, and three new enzymes called CMY-
25, CMY-27 and CMY-40 were detected. Seven out of the 117
isolates (6%) also produced an extended-spectrum b-lactamase.
As acquired AmpC enzymes are likely to become a serious
public health issue worldwide, close surveillance is necessary to
curb their spread.
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Acquired AmpCs appeared in the late 1980s and have been
detected mainly in isolates of Klebsiella spp., Escherichia coli,
Proteus mirabilis and Salmonella spp. although they have also
been identified in other species including natural AmpC
producers [1]. These enzymes confer resistance to most
b-lactams – including cephamycins – with the exception of
cefepime and carbapenems [2].
Most acquired ampCs derive from chromosomal ampC
genes of the family Enterobacteriaceae (Citrobacter freundii,
Enterobacter spp., Morganella morganii and Hafnia alvei)
whereas the origin of others remains unknown. Isolates har-
bouring acquired ampCs are usually multi-resistant [3–6], lim-
iting the therapeutic options even further. In this context,
we aimed to determine the prevalence of acquired AmpCs
in Enterobacteriaceae isolates lacking inducible chromosomal
ampC genes at a Spanish hospital from January 1999 to
December 2007.
Isolates were obtained from routine cultures at the Hospi-
tal de la Santa Creu i Sant Pau (Barcelona, Spain). When
there were multiple isolates from a patient within a 30-day
period, only one was considered for analysis. Isolates were
identified using standard methods [7]. The disc diffusion sus-
ceptibility test was performed according to Clinical Labora-
tory Standards Institute (CLSI) guidelines [8], using
commercially available discs (Bio-Rad, Marnes La Coquette,
France). The production of Extended-spectrum beta-lacta-
mase (ESBL) was studied using the double-disc synergy test
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